By the Top Tier Newswire AI Desk · September 30, 2026 at 9:46 AM ET · reviewed against 5 wire stories
CELCUITY INC (CELC) is drawing unusual attention today. Our newswire has captured 5 stories on CELC across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
CELC stock is moving today after the company announced the commercial availability of REVTORPYK in the U.S. for a specific subset of breast cancer patients. The stock opened with a 1.4% gap up and reached a session high of $88.68 in early trading before retreating to $80.04 in late afternoon. The move follows FDA approval of the drug on July 14, 2026, and the company’s confirmation that the treatment is now accessible to eligible HR+/HER2- advanced breast cancer patients without a detected PIK3CA mutation.
What Happened
Celcuity Inc. (CELC) announced on September 30, 2026, that REVTORPYK (gedatolisib) is now commercially available in the U.S. The drug is indicated for patients with HR+/HER2- advanced breast cancer who have progressed on or after at least one line of endocrine therapy in the metastatic setting and do not have a PIK3CA mutation. This development was disclosed in a Form 8-K filed with the SEC and reported by multiple outlets including The Fly and MarketChameleon. The commercial availability marks a key milestone for Celcuity, which has been working to expand access to the drug since its approval.
What The Data Shows
The intraday session showed a strong opening gap up, with the stock reaching a high of $88.68 shortly after the market opened. Volume has been elevated at 0.8 million shares traded, which is 0.6 times the 3-month daily average. The stock has traded in a 52-week range of $44.42 to $151.02 and is currently valued at a market cap of $3.9 billion. Over the last 8 sessions, the stock has declined 2.9%, from $80.61 to $78.24. On September 30, the stock printed two fresh 52-week highs and three fresh 52-week lows.
What To Watch
The stock will be watched for continued volume expansion and price stability ahead of any potential analyst coverage updates. Investors should also monitor Celcuity’s upcoming corporate actions and any new drug developments.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
CELC · today's session (5-min) · +1.54% vs prior close · updated 2:03 PM ETAI sentiment, last 36h · averaged over 5 stories · 63/100 bullish
The headlines behind the move
Story flow · 5 stories on the wire, last 36h · hover or tap a dot for the headline
4h agoMarketChameleonBULLISH 67Product/PR
CELC Launches REVTORPYK in the U.S. for HR+/HER2- Advanced Breast Cancer Without PIK3CA Mutation
September 30, 2026
Celcuity said REVTORPYK (gedatolisib) is now commercially available in the U.S. for eligible patients with HR+/HER2- locally advanced or metastatic breast cancer without a PIK3CA mutation detected after progression on endocrine therapy. The company highlighted Phase 3 VIKTORIA-1 results showing a 76% (triplet) and 67% (doublet) reduction in risk of disease progression or death versus fulvestrant, and noted an sNDA submitted in August aimed at expanding use to PIK3CA-mutated disease.
4h agoMarketChameleonBULLISH 73Product/PR
Celcuity says REVTORPYK is now commercially available in the U.S., expanding access after July FDA approval
September 30, 2026
Celcuity (CELC) said REVTORPYK (gedatolisib) is now commercially available in the U.S. for eligible HR+/HER2- advanced breast cancer patients without a detected PIK3CA mutation, following FDA approval on July 14, 2026. The company highlighted Phase 3 VIKTORIA-1 results in the PIK3CA wild-type cohort showing a 76% and 67% reduction in risk of progression or death versus fulvestrant for the triplet and doublet regimens, respectively. Celcuity also pointed to its REVTORPYK Support Services…
5h agoThe FlyBULLISH 63Product/PR
Celcuity announces REVTORPYK is now commercially available in U.S.
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
REVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or after at least one line of endocrine therapy in the metastatic setting
Frequently asked questions
Why is CELC stock moving today?
CELCUITY INC (CELC) is drawing unusual attention today. Our newswire has captured 5 stories on CELC across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100). The most recent driver: "CELC Launches REVTORPYK in the U.S. for HR+/HER2- Advanced Breast Cancer Without PIK3CA Mutation
September 30, 2026" (MarketChameleon).
Is CELC a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of CELC coverage reads 63/100 over 5 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →